GlassScriptPhysician profile
Mehmet Akce
NPI 1639480106
$63,479.10
in general payments reported to CMS, 2019-2025
26 companies · $15K in 2025
The $15K reported for 2025 was more than what 91% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,662 · 2020: $6,703 · 2021: $3,000 · 2022: $4,677 · 2023: $14K · 2024: $17K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $42K · Travel and Lodging: $2,716 · Food and Beverage: $2,096 · Education: $39.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $41,585.00 |
| Travel and Lodging | $2,716.22 |
| Food and Beverage | $2,096.04 |
| Education | $39.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $10,410.52 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $10,195.82 | 2022-2025 | Imfinzi |
| Glaxosmithkline, LLC. | $9,275.00 | 2020-2024 | |
| Astrazeneca Uk Limited | $8,354.99 | 2023-2025 | Imfinzi |
| Eisai INC. | $6,290.00 | 2019-2025 | |
| Exelixis INC. | $4,967.80 | 2020-2023 | |
| Partner Therapeutics, INC. | $4,096.77 | 2025 | Bizengri |
| Incyte Corporation | $2,375.56 | 2023 | |
| Daiichi Sankyo INC. | $1,935.00 | 2024 | |
| Taiho Oncology, INC. | $1,650.00 | 2023 | |
| Genentech USA, INC. | $1,555.00 | 2022 | |
| Merck Sharp & Dohme LLC | $927.98 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $823.46 | 2022-2024 | |
| Redhill Biopharma INC. | $177.77 | 2020 | |
| Gilead Sciences, INC. | $149.61 | 2025 | Trodelvy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $117.19 | 2022-2023 | |
| Ipsen Biopharmaceuticals, INC | $97.37 | 2019-2024 | Onivyde, Somatuline Depot |
| Tesaro, INC. | $23.94 | 2019 | |
| Aveo Pharmaceuticals, INC. | $21.53 | 2022 | |
| Sobi, INC | $19.93 | 2025 | |
| Pfizer INC. | $13.86 | 2023 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mehmet Akce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.